Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,214.08 +26.41 (+0.51%) Dow
39,387.76 +331.36 (+0.85%) Nasdaq
16,346.26 +43.46 (+0.27%) Bitcoin USD
62,532.75 +1,063.06 (+1.73%) CMC Crypto 200
1,343.88 +43.78 (+3.37%)
Cytek Biosciences, Inc. (CTKB)
After hours:
| Previous close | 6.27 |
| Open | 6.35 |
| Bid | 6.19 x 300 |
| Ask | 6.24 x 100 |
| Day's range | 6.07 - 6.55 |
| 52-week range | 3.80 - 9.87 |
| Volume | |
| Avg. volume | 719,601 |
| Market cap | 813.837M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings date | 05 Aug 2024 - 10 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- GuruFocus.com
Cytek Biosciences Inc (CTKB) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Explore how Cytek Biosciences Inc navigates through revenue growth and operational expansions while addressing financial hurdles in the first quarter of 2024.
ZacksCytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 80% and 2.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCytek Biosciences Reports First Quarter 2024 Financial Results
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the prod
